{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "COVID-19",
      "Coronavirus",
      "DPP4",
      "DPP4 inhibitors",
      "Diabetes",
      "Dipeptidyl peptidase 4",
      "SARS-CoV-2"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "32946854",
  "DateCompleted": {
    "Year": "2021",
    "Month": "02",
    "Day": "15"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "02",
    "Day": "15"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2020",
        "Month": "09",
        "Day": "16"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.diabres.2020.108444",
      "S0168-8227(20)30697-5"
    ],
    "Journal": {
      "ISSN": "1872-8227",
      "JournalIssue": {
        "Volume": "171",
        "PubDate": {
          "Year": "2021",
          "Month": "Jan"
        }
      },
      "Title": "Diabetes research and clinical practice",
      "ISOAbbreviation": "Diabetes Res Clin Pract"
    },
    "ArticleTitle": "Use of DPP4 inhibitors in Italy does not correlate with diabetes prevalence among COVID-19 deaths.",
    "Pagination": {
      "StartPage": "108444",
      "MedlinePgn": "108444"
    },
    "Abstract": {
      "AbstractText": [
        "In a nationwide study of 3818 charts from patients with fatal COVID-19, we found that geographical differences in Dipeptidyl peptidase 4 (DPP4) inhibitors use did not correlate with diabetes prevalence among COVID-19 deaths, thus not supporting the hypothesis of a clinically relevant involvement of DPP4 inhibition in COVID-19 development and progression."
      ],
      "CopyrightInformation": "Copyright \u00a9 2020 Elsevier B.V. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Medicine, Unit of Endocrinology & Diabetes, Campus Bio-Medico University of Rome, Italy."
          }
        ],
        "LastName": "Strollo",
        "ForeName": "Rocky",
        "Initials": "R"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Experimental Medicine, Sapienza University of Rome, Italy."
          }
        ],
        "LastName": "Maddaloni",
        "ForeName": "Ernesto",
        "Initials": "E"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Internal Medicine, Section of Endocrinology and Diabetes, South-Tyrolean Healthcare System, Bolzano General Hospital, Bolzano, Italy."
          }
        ],
        "LastName": "Dauriz",
        "ForeName": "Marco",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Medicine, Unit of Geriatrics, Campus Bio-Medico University of Rome, Italy."
          }
        ],
        "LastName": "Pedone",
        "ForeName": "Claudio",
        "Initials": "C"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Experimental Medicine, Sapienza University of Rome, Italy."
          }
        ],
        "LastName": "Buzzetti",
        "ForeName": "Raffaella",
        "Initials": "R"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Medicine, Unit of Endocrinology & Diabetes, Campus Bio-Medico University of Rome, Italy. Electronic address: p.pozzilli@unicampus.it."
          }
        ],
        "LastName": "Pozzilli",
        "ForeName": "Paolo",
        "Initials": "P"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Ireland",
    "MedlineTA": "Diabetes Res Clin Pract",
    "NlmUniqueID": "8508335",
    "ISSNLinking": "0168-8227"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Dipeptidyl-Peptidase IV Inhibitors"
    },
    {
      "RegistryNumber": "EC 3.4.14.5",
      "NameOfSubstance": "DPP4 protein, human"
    },
    {
      "RegistryNumber": "EC 3.4.14.5",
      "NameOfSubstance": "Dipeptidyl Peptidase 4"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "mortality",
        "transmission",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [
        "drug therapy",
        "epidemiology",
        "virology"
      ],
      "DescriptorName": "Diabetes Mellitus"
    },
    {
      "QualifierName": [
        "chemistry"
      ],
      "DescriptorName": "Dipeptidyl Peptidase 4"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Dipeptidyl-Peptidase IV Inhibitors"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "epidemiology"
      ],
      "DescriptorName": "Italy"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Prevalence"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Prognosis"
    },
    {
      "QualifierName": [
        "drug effects",
        "isolation & purification"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Survival Rate"
    }
  ],
  "CoiStatement": "Conflict of interests RS, MD and CP have no conflict of interest to declare for the preparation of this manuscript. EM has received speaker fees from Astra-Zeneca and Lilly and research grants from scientific societies with the unrestricted support from AstraZeneca. PP has received speaker fees from AstraZeneca, MSD and Lilly. RB has received speaker fees from AstraZeneca, MSD and Lilly"
}